Namwiwat Medical Corporation PCL (BKK:NAM)
Thailand · Delayed Price · Currency is THB 3.800
0.00 (0.00%)
At close: Feb 10, 2026
BKK:NAM Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,785 | 1,114 | 1,101 | 1,099 | 995.36 | 676.61 |
Other Revenue | 1.04 | 1.96 | 2.32 | 0.99 | - | 2.22 |
| 1,786 | 1,116 | 1,103 | 1,100 | 995.36 | 678.84 | |
Revenue Growth (YoY) | 85.24% | 1.20% | 0.25% | 10.55% | 46.63% | - |
Cost of Revenue | 1,234 | 646.51 | 620.7 | 772.91 | 654.73 | 467.39 |
Gross Profit | 552.35 | 469.84 | 482.38 | 327.45 | 340.63 | 211.45 |
Selling, General & Admin | 353.43 | 255.54 | 230.16 | 103.39 | 115.18 | 65.31 |
Operating Expenses | 353.43 | 255.54 | 230.16 | 103.39 | 115.18 | 65.31 |
Operating Income | 198.92 | 214.29 | 252.22 | 224.06 | 225.45 | 146.14 |
Interest Expense | -24.82 | -12.68 | -15.73 | -12.99 | -14.03 | -12.46 |
Interest & Investment Income | 11.18 | 15.64 | 1.57 | 1.06 | 0.02 | 0.02 |
Earnings From Equity Investments | - | - | - | -0.55 | -0.27 | -11.4 |
Currency Exchange Gain (Loss) | -1.15 | 9.46 | - | 13.04 | 1.14 | - |
Other Non Operating Income (Expenses) | 8.17 | 5.1 | 1.65 | -8.14 | - | - |
EBT Excluding Unusual Items | 192.3 | 231.8 | 239.71 | 216.48 | 212.3 | 122.3 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 10.65 |
Gain (Loss) on Sale of Assets | - | 0.14 | 10.57 | 5.44 | 1.48 | - |
Pretax Income | 192.3 | 231.94 | 250.28 | 221.91 | 213.78 | 132.95 |
Income Tax Expense | 40.58 | 49.12 | 49.53 | 46.2 | 44.1 | 22.51 |
Earnings From Continuing Operations | 151.71 | 182.83 | 200.75 | 175.71 | 169.68 | 110.44 |
Minority Interest in Earnings | -24.22 | -1.96 | - | - | 4.97 | 1.39 |
Net Income | 127.49 | 180.87 | 200.75 | 175.71 | 174.65 | 111.83 |
Net Income to Common | 127.49 | 180.87 | 200.75 | 175.71 | 174.65 | 111.83 |
Net Income Growth | -26.87% | -9.90% | 14.25% | 0.61% | 56.17% | - |
Shares Outstanding (Basic) | 700 | 700 | 615 | 26 | 20 | 20 |
Shares Outstanding (Diluted) | 700 | 700 | 615 | 26 | 20 | 20 |
Shares Change (YoY) | 0.97% | 13.90% | 2237.63% | 31.45% | - | - |
EPS (Basic) | 0.18 | 0.26 | 0.33 | 6.68 | 8.73 | 5.59 |
EPS (Diluted) | 0.18 | 0.26 | 0.33 | 6.68 | 8.73 | 5.59 |
EPS Growth | -27.56% | -20.90% | -95.11% | -23.46% | 56.17% | - |
Free Cash Flow | 43.76 | -42.62 | 228.27 | -81.16 | 93.61 | 104.71 |
Free Cash Flow Per Share | 0.06 | -0.06 | 0.37 | -3.09 | 4.68 | 5.24 |
Dividend Per Share | 0.150 | 0.150 | 0.090 | - | - | - |
Dividend Growth | 66.67% | 66.67% | - | - | - | - |
Gross Margin | 30.92% | 42.09% | 43.73% | 29.76% | 34.22% | 31.15% |
Operating Margin | 11.13% | 19.20% | 22.86% | 20.36% | 22.65% | 21.53% |
Profit Margin | 7.14% | 16.20% | 18.20% | 15.97% | 17.55% | 16.47% |
Free Cash Flow Margin | 2.45% | -3.82% | 20.69% | -7.38% | 9.40% | 15.43% |
EBITDA | 234.04 | 240.24 | 277.45 | 241.25 | 239.88 | - |
EBITDA Margin | 13.10% | 21.52% | 25.15% | 21.93% | 24.10% | - |
D&A For EBITDA | 35.12 | 25.94 | 25.23 | 17.19 | 14.43 | - |
EBIT | 198.92 | 214.29 | 252.22 | 224.06 | 225.45 | 146.14 |
EBIT Margin | 11.13% | 19.20% | 22.86% | 20.36% | 22.65% | 21.53% |
Effective Tax Rate | 21.11% | 21.18% | 19.79% | 20.82% | 20.63% | 16.93% |
Revenue as Reported | 1,793 | 1,131 | 1,115 | 1,111 | 997.98 | 678.84 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.